Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Announces Earnings Results

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) issued its earnings results on Tuesday. The company reported $0.88 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $770.90 million for the quarter.

Recordati Industria Chimica E Farmaceutica Stock Performance

OTCMKTS RCDTF remained flat at $56.95 on Thursday. The stock’s fifty day moving average price is $61.03 and its 200-day moving average price is $63.90. Recordati Industria Chimica E Farmaceutica has a 12 month low of $49.00 and a 12 month high of $65.44. The stock has a market capitalization of $11.75 billion, a P/E ratio of 16.90 and a beta of 0.26. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.16 and a current ratio of 1.64.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on RCDTF shares. Kepler Capital Markets raised Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 3rd. Barclays raised Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a report on Thursday, February 12th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Recordati Industria Chimica E Farmaceutica currently has an average rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.